Prof. Dr. Malcolm Macleod

Malcolm Macleod, BSc(Hons) MBChB PhD FRCP Ed, is Professor of Neurology and Translational Neuroscience at the University of Edinburgh, head of Neurology at Forth Valley Royal Hospital, and Honorary Principal Research Fellow, Florey Neurosciences Unit, Melbourne, Australia.  Prof. Macleod was a founding co-ordinator of the Collaborative Approach to Meta-Analysis and Review of Animal Data in Experimental Studies (CAMARADES), leader in advancing education about systematic reviews in animal research. Prof. Macleod is a member of the UK Home Office Animals in Science Committee.

Publication highlights:

Macleod MR, Lawson McLean A, Kyriakopoulou A, Serghiou S, de Wilde A, Sherratt N, Hirst T, Hemblade R, Bahor Z, Nunes-Fonseca C, Potluru A, Thomson A, Baginskitae J, Egan K, Vesterinen H, Currie GL, Churilov L, Howells DW, Sena ES (2015) Risk of Bias in Reports of In Vivo Research: A Focus for Improvement. PLoS Biol 13 (10): e1002273.

Macleod MR, Michie S, Roberts I, Dirnagl U, Chalmers I, Ioannidis JP, Al-Shahi Salman R, Chan AW, Glasziou P (2014) Biomedical research: increasing value, reducing waste. Lancet 383 (9912): 101-4.

Landis SC, Amara SG, Asadullah K, Austin CP, Blumenstein R, Bradley EW, Crystal RG, Darnell RB, Ferrante RJ, Fillit H, Finkelstein R, Fisher M, Gendelman HE, Golub RM, Goudreau JL, Gross RA, Gubitz AK, Hesterlee SE, Howells DW, Huguenard J, Kelner K, Koroshetz W, Krainc D, Lazic SE, Levine MS, Macleod MR, McCall JM, Moxley RT 3rd, Narasimhan K, Noble LJ, Perrin S, Porter JD, Steward O, Unger E, Utz U, Silberberg SD (2012) A call for transparent reporting to optimize the predictive value of preclinical research. Nature 490 (7419): 187-91.

Dr. Magali Haas

Magali Haas is CEO and President of Cohen Veterans Bioscience, a non-profit brain research organization based in Cambridge, MA. She previously served as founding Chief Science and Technology Officer for One Mind for Research.  Magali has over 15 years of pharmaceutical executive and clinical research experience, predominantly at Johnson & Johnson, where she assumed broad end-to-end development leadership roles. As an “intrapreneur” she established the first CNS Translational Medicine & Integrative Solutions departments, and co-founded the first Companion Diagnostics Center of Excellence as well as J&J’s Healthcare Innovation team. Magali earned her BS in bioengineering from the University of Pennsylvania, an MS in biomedical engineering from Rutgers University, and her MD and PhD in neuroscience from Albert Einstein College of Medicine.

Publication highlight:

Steckler T, Brose K, Haas M, Kas MJ, Koustova E, Bespalov A; ECNP Preclinical Data Forum Network (2015) The preclinical data forum network: A new ECNP initiative to improve data quality and robustness for (preclinical) neuroscience. Eur Neuropsychopharmacol 25 (10): 1803-7.

Dr. Dario Doller

Dario Doller was born, raised and educated in Buenos Aires, Argentina. In 1989, he earned a PhD at the Universidad de Buenos Aires working with Prof. E.G. Gros on the synthesis and spectroscopic properties of steroidal glycoalkaloids from the tomato plant. He took off to College Station, TX, to join Prof. Derek Barton (Nobel Laureate 1969) research group at Texas A&M University. Dario has 20+ years of experience in the pharmaceutical industry, including large pharma (Schering-Plough Research Institute) and small biotech companies (3-DP, Gliatech and Neurogen). His most recent position was at Lundbeck Research USA, where he studied for a decade the chemical biology of GPCR allosteric modulators. Dario contributed to a marketed drug (PAR-1 antagonist vorapaxar), and 2 clinical compounds (MCHR-1 antagonist NGD-4715 and mGluR5 NAM Lu AF09535), as well as several tool compounds and radioligands for translational studies in novel targets. His work is documented by over 100 peer reviewed articles, patent applications and book chapters.

Dr. Bruce Altevogt

Bruce Altevogt, PhD, is a Director of Science Policy and Science Advocacy within Pfizer Inc.’s Global Policy and International Public Affairs. In this role, Dr. Altevogt is responsible for managing policy issues in support of Pfizer’s research & development enterprise. In addition, he is responsible for developing and implementing a science advocacy platform, which includes a public affairs and stakeholder management functions.  Finally, he provides policy support for the Neuroscience and Pain, Vaccines, and Established Products business units. Prior to joining Pfizer Inc. Dr. Altevogt spent over 11 years as a senior program officer at the U.S. Institute of Medicine (IOM) leading policy initiatives related to basic and translational research, drug discovery and development, and preparedness for catastrophic events. Dr. Altevogt received his doctorate from Harvard University’s Program in Neuroscience and his B.A. from the University of Virginia in Charlottesville, where he majored in Biology and minored in South Asian Studies.

Publication highlights:

Pankevich DE, Altevogt BM, Dunlop J, Gage FH, Hyman SE (2014) Improving and accelerating drug development for nervous system disorders. Neuron 84 (3): 546-53.

Gostin LO, Altevogt BM, Pope AM (2014) Future oversight of recombinant DNA research: recommendations of an Institute of Medicine committee. JAMA 311 (7): 671-2.

Altevogt BM, Pankevich DE, Pope AM, Kahn JP (2012) Research agenda. Guiding limited use of chimpanzees in research. Science 335 (6064): 41-2.

Prof. Dr. Khusru Asadullah

Khusru Asadullah, MD, is Professor of Medicine at the department of Dermatology, Charité – Berlin Medical School, Chairman of the Management Board of German Skin Research Center, board certified consultant for Dermatology, Venerology, Allergology and Immunology, former Vice-President Target Discovery at Bayer-Schering Pharma.

Publication highlights:

Asadullah K, Busch A, Gottwald M, Reinke P, Landeck L (2015) Industry-academia collaborations for biomarkers. Nat Rev Drug Discov 14 (12): 805-6.

Prinz F, Schlange T, Asadullah K (2011) Believe it or not: how much can we rely on published data on potential drug targets? Nat Rev Drug Discov 10 (9): 712.

Prof. Dr. Ulrich Dirnagl

Ulrich Dirnagl, MD, PhD, is the Director of the Department of Experimental Neurology at the Charité Universitätsmedizin Berlin, Chief Executive Director of the Center for Stroke Research Berlin, Clinical program coordinator of the Excellence Cluster NeuroCure and the Berlin partner site of the German Center for Neurodegenerative Diseases (DZNE), as well as Program Director of the International Graduate Program Medical Neuroscience. Prof. Dirnagl studied medicine at Ludwig Maximilians University in Munich, where he also obtained a PhD in Neuroscience. The research of Ulrich Dirnagl is focused on stroke, cerebral blood flow regulation, and brain imaging. To improve the predictiveness of preclinical translational research, he is actively promoting the introduction of quality standards for experimental design and reporting, as well as international collaboration in large, phase III-type preclinical trials.

Publication highlights:

Dirnagl U, Przesdzing I (2016) A pocket guide to electronic laboratory notebooks in the academic life sciences. F1000 Res 5:2.

Holman C, Piper SK, Grittner U, Diamantaras AA, Kimmelman J, Siegerink B, Dirnagl U (2016) Where have all the rodents Gone? The effects of attrition in experimental research on cancer and stroke. PLoS Biol 14(1):e1002331.

Begley CG, Buchan AM, Dirnagl U (2015) Robust research: Institutions must do their part for reproducibility. Nature 525: 25-7.

Arnoud Herremans

Arnoud Herremans is a psychologist by training (Utrecht University), holds a PhD in Neuroscience (Utrecht University) and has been leading a pharmacology department at Solvay until 2010. During the years at Solvay, Arnoud introduced Operational Excellence and Lean management in the pharmaceutical discovery operations and witnessed great improvements in productivity as well as the enhancement of ownership and entrepreneurial drive within the team. In 2010, Arnoud has started an independent company, called Y47, with the mission to bring continuous improvement and Innovation Excellence to Life Science and Chemical organizations where research is an important part of their work. Since March 2016, PAASP and Y47 have been collaborating and this collaboration has taken now a new form where Arnoud will provide strategic leadership to some of the PAASP’s initiatives and will particularly focus on the interaction with our partners and colleagues in the Benelux countries.

Björn Gerlach

Björn Gerlach studied biology at the University of Giessen, Germany, to obtain his Diploma with a focus on immunology, microbiology and biochemistry. He started his PhD at the German Cancer Research Centre in Heidelberg but after one year moved with his supervisor, Prof. Dr. Henning Walczak, to Imperial College London. After obtaining the PhD degree, Björn moved back to Germany to join Abbott (later AbbVie) as a Postdoctoral Fellow. He worked on biomarkers in the field of neurodegenerative diseases and neuroprotective / neurodegenerative therapies. Beside the lab work, Björn managed externally funded PPP projects where his responsibilities ranged from contract management to supervision of the research at CROs.

Christoph Emmerich

Christoph Emmerich, a Biochemist by training, carried out his PhD studies in the fields of cancer biology and apoptosis at the German Cancer Research Centre (DKFZ), Heidelberg and at the Imperial College London. In 2011, Christoph joined the MRC Protein Phosphorylation and Ubiquitylation Unit (MRC-PPU) in Dundee, Scotland where he was involved in several industry-academic collaborations with the main aim to help accelerate the development of future drugs targeting protein kinases and the ubiquitylation system for the improved treatment of disease. His work is published in high impact factor journals and his projects were based on regulatory mechanisms of the Immune system, with an increasing focus on data quality and integrity standards.

Malgorzata Pietraszek

Malgorzata Pietraszek has over 20 years of experience in CNS pharmacology acquired in both pharmaceutical industry and academic environments. Malgorzata holds a PhD from the Institute of Pharmacology Polish Academy of Sciences (PAS) in Cracow, Poland and MSc from Jagiellonian University, Cracow, Poland. Between 1993 and 2007, Malgorzata conducted research in the therapeutic areas of schizophrenia and Parkinson’s disease at the Institute of Pharmacology PAS in Cracow. During this time, she maintained active collaborations with other departments of the Institute and external partners from academia and pharmaceutical industry that resulted in numerous publications and meeting presentations. In 2007, Malgorzata joined Merz Pharmaceuticals (Germany) as a scientific expert involved in preclinical drug research and development program in different CNS indications and stayed in this role till 2014. She implemented many in vivo models, trained postdocs and technicians and organized internal workshops to accelerate drug research and development in the therapeutic areas of schizophrenia and neurodegenerative disorders. She also supported clinical development in the therapeutic areas of CNS disorders. Malgorzata established and managed collaborations with key opinion experts from academia as well as with many Contract Research Organizations. Additionally, she was involved in in vivo preclinical data quality assessment.